Aspirin Use and Respiratory Morbidity in COPD: a Propensity Score Matched Analysis in SPIROMICS.
Chest. 2018 Dec 26;:
Authors: Fawzy A, Putcha N, Aaron CP, Bowler RP, Comellas AP, Cooper CB, Dransfield MT, Han MK, Hoffman EA, Kanner RE, Krishnan JA, Labaki WW, Paine R, Paulin LM, Peters SP, Wise R, Barr RG, Hansel NN, SPIROMICS Investigators
BACKGROUND: Aspirin use in COPD has been associated with reduced all-cause mortality in meta-regression analysis with few equivocal studies. However, aspirin’s effect on COPD morbidity is unknown.
METHODS: Self-reported daily aspirin use was obtained at baseline from SPIROMICS participants with COPD (FEV1/FVC<70%). Acute exacerbations of COPD (AECOPD) were prospectively ascertained through quarterly structured telephone questionnaires up to 3 years and categorized as moderate (symptoms treated with antibiotics or oral corticosteroids) or severe (requiring emergency department visit or hospitalization). Aspirin users were matched one-to-one with non-users based on propensity score. The association of aspirin use with total, moderate, and severe AECOPD was investigated using zero-inflated negative binomial models. Linear or logistic regression were used to investigate the association with baseline respiratory symptoms, quality of life, and exercise tolerance.
RESULTS: Among 1,698 participants, 45% reported daily aspirin use at baseline. Propensity score matching resulted in 503 participant-pairs. Aspirin users had lower incidence rate of total AECOPD (adjusted incidence rate ratio [IRR] 0.78, 95% Confidence Interval [CI]: 0.65-0.94), with similar effect for moderate but not severe AECOPD (IRR 0.86, 95%CI: 0.63-1.18). Aspirin use was associated with lower total St. George Respiratory Questionnaire score (β -2.2, 95%CI: -4.1, -0.4), reduced odds of moderate-severe dyspnea (modified Medical Research Council questionnaire score ≥2 adjusted odds ratio 0.69, 95%CI: 0.51-0.93), and COPD Assessment Test score (β -1.1; 95%CI: -1.9, -0.2) but not six-minute walk distance (β 0.7 meters; 95%CI: -14.3, 15.6).
CONCLUSIONS: Daily aspirin use is associated with reduced rate of COPD exacerbations, less dyspnea and better quality of life. Randomized clinical trials of aspirin use in COPD are warranted to account for unmeasured and residual confounding.
PMID: 30593776 [PubMed – as supplied by publisher]